Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2007, Vol. 12 ›› Issue (11): 1317-1320.

Previous Articles    

Efficiency and safety of Fraxiparin for patients with acute coronary syndrome

YAN Yu-xiang1, LI Jing2, GUO mei3, LIU Deng-xian3   

  1. 1Department of Epidemiology and Biostatistics, School of Public Health and Family Medicine, Capital Medical University; 2Beijing Tongren Hospital,Capital Medical University; 3Beijing Friendship Hospital,Capital Medical University,Beijing 100069,China
  • Received:2007-02-09 Revised:2007-05-02 Published:2020-11-04

PDF (PC)

108

Abstract: AIM: To evaluate the efficiency and safety of Fraxiparin for patients with acute coronary syndrome (ACS). METHODS: 137 patients with ACS were randomly assigned to Fraxiparin treatment or enoxaparin treatment for seven days. RESULTS: 129 cases completed the whole trial and the results were obtained from ITT. The heart death rate is not statistically different between the two groups during the treatment. There are no Q segment acute myocardial infarction happened. Both drugs statistically decreased CK, CKMB and TnT, There was no significant difference between the two groups regarding these changes. Only two minor adverse reactions happened and became normal soon after Nadroparin withdrew. CONCLUSION: Fraxiparin and enoxaparin have similar efficiency and safety in the treatment of patients with ACS.

Key words: Fraxiparin, enoxaparin, acute coronary syndrome, efficiency, safety

CLC Number: